Abstract:Background: The identification of mutated proteins in human cancer cells-termed proteogenomics, requires several technologically independent research methodologies including DNA variant identification, RNA sequencing, and mass spectrometry. Any one of these methodologies are not optimized for identifying potential mutated proteins and any one output fails to cover completely a specific landscape. Methods: An isogenic melanoma cell with a p53-null genotype was created by CRISPR/CAS9 system to determine how p53 gene inactivation affects mutant proteome expression. A mutant peptide reference database was developed by comparing two distinct DNA and RNA variant detection platforms using these isogenic cells. Chemically fractionated tryptic peptides from lysates were processed using a TripleTOF 5600+ mass spectrometer and their spectra were identified against this mutant reference database. Results: Approximately 190 mutated peptides were enriched in wt-p53 cells, 187 mutant peptides were enriched in p53-null cells, with an overlap of 147 mutated peptides. STRING analysis highlighted that the wt-p53 cell line was enriched for mutant protein pathways such as CDC5L and POLR1B, whilst the p53-null cell line was enriched for mutated proteins comprising EGF/YES, Ubiquitination, and RPL26/5 nodes. Conclusion: Our study produces a well annotated p53-dependent and p53-independent mutant proteome of a common melanoma cell line model. Coupled to the application of an integrated DNA and RNA variant detection platform (CLCbio) and software for identification of proteins (ProteinPilot), this pipeline can be used to detect high confident mutant proteins in cells. General significance: This pipeline forms a blueprint for identifying mutated proteins in diseased cell systems.

Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation

A Genomewide Study Identifies the Wnt Signaling Pathway As a Major Target of P53 in Murine Embryonic Stem Cells

Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability

p53 and stem cells: new developments and new concerns.

Targeting mutant p53 stabilization for cancer therapy

P53 and Stem Cells: New Developments and New Concerns

A New Role for P53 in Maintaining Genetic Stability in Embryonic Stem Cells

Alterations Of The P53 Tumor-Suppressor Gene In Transformed Mouse-Liver Cells

Fine-tuning P53 Activity Through C-terminal Modification Significantly Contributes to HSC Homeostasis and Mouse Radiosensitivity.

Mutant p53 as a guardian of the cancer cell

Network effect of Wt-mutant p53 interactions and implications on p53 gene therapy.

p57 Suppresses the Pluripotency and Proliferation of Mouse Embryonic Stem Cells by Positively Regulating p53 Activation

Mouse models to investigate in situ cell fate decisions induced by p53

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy

Regulation of Apoptosis and Differentiation by P53 in Human Embryonic Stem Cells*

The effects of p53 gene inactivation on mutant proteome expression in a human melanoma cell model

In Silico Screening, Molecular Dynamics Simulation and Binding Free Energy Identify Single-Point Mutations That Destabilize p53 and Reduce Binding to DNA

Promising Proteolysis-Targeting Chimera for Mutant p53-R175H

Generation and Characterization of P53 Mutant Mice.

Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins

Exploring the Functions of Mutant p53 through TP53 Knockout in HaCaT Keratinocytes